Peficitinib

吡西替尼

Report date: 2025/11/21 16:05:47
NME

Base Information

Drug NamePeficitinib
Drug Alias Name培西替尼peficitinibPeficitinib hydrobromide氢溴酸吡西替尼peficitinibum +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase 2 inhibitorsTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase JAK3 inhibitors +[4] 
TargetsTyrosine-protein kinase 2Tyrosine-protein kinase JAK2Tyrosine-protein kinase JAK3 +[4] 
Therapy Area/IndicationsPsoriasisColitis, UlcerativeArthritis, Rheumatoid
Global Approved IndicationsArthritis, Rheumatoid
Approved Indications in ChinaArthritis, Rheumatoid
Original Approved Country/TerritoryJapan
Original Approved Date2019/03/29
Country/TerritoryCzechiaBelgiumBulgaria +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstellas Pharma Inc Yaizu Technology CenterAstellas Pharma IncAstellas Pharma China Inc +[4] 
Inactive CompaniesAstellas Pharma Tech Co Ltd Yaizu Technology CenterAstellas Pharma Global Development IncJanssen Biotech Inc +[4] 
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsPsoriasisColitis, Ulcerative

Other Information

ATC CodeM01C
Related LinksDrugBankKEGG